- Axio has partnered with Ark Biotech to integrate AI-driven process development with in silico bioreactor models for biologics manufacturing.
- The collaboration aims to shorten development timelines, reduce costs, and improve reliability in scaling up biologics production.
Axio has announced a partnership with Ark Biotech to enhance the speed and precision of biologics manufacturing. Ark’s in silico bioreactor models allow designs to be tested, refined, and validated in a virtual environment before laboratory implementation.
The collaboration enables Axio’s AI-driven process development to connect directly with predictive bioreactor modelling. This integration shortens the feedback loop between design and scale-up, streamlining biologics manufacturing processes.
According to Axio, the initiative is intended to remove months from development timelines, cut costs, and improve the reliability of manufacturing processes from the start.
